The European Association of Urology (EAU) suggests stratifying PCa based on risk factors, such as prostate-specific antigen (PSA) and Gleason score (GS), to assist medical professionals in the evidence-based management of different risk PCa and predict recurrence risk after definitive treatment (5). This evidence concerns the gene KLK3 and posterior cortical atrophy.